CEL SCI Corp (CVM) stock
CVMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$1.19−0.12 (-9.16%)
Close on Nov 12, 2026Market cap $20.93MP/E –Yield –
Cel Sci r&d expenses
Research and development expenses are spending on new products and technology.
Cel Sci's R&D Expenses for the twelve months ending Jun 30, 2026 was $14.80M, down 11.2% year over year. For fiscal 2025 it was $15.89M, down 12.5% from the year before. Over ten years it grew -1.9% a year on average. The highest annual figure on record is $25.36M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $15.89M | -12.5% |
| FY2024 | Sep 30, 2024 | $18.16M | -19.2% |
| FY2023 | Sep 30, 2023 | $22.47M | -11.4% |
| FY2022 | Sep 30, 2022 | $25.36M | +9.7% |
| FY2021 | Sep 30, 2021 | $23.11M | +29.5% |
| FY2020 | Sep 30, 2020 | $17.84M | +40.9% |
| FY2019 | Sep 30, 2019 | $12.66M | +16.0% |
| FY2018 | Sep 30, 2018 | $10.91M | -30.1% |
| FY2017 | Sep 30, 2017 | $15.61M | -10.5% |
| FY2016 | Sep 30, 2016 | $17.45M | -9.1% |
| FY2015 | Sep 30, 2015 | $19.19M | +25.7% |
| FY2014 | Sep 30, 2014 | $15.27M | +20.4% |
| FY2013 | Sep 30, 2013 | $12.68M | +22.3% |
| FY2012 | Sep 30, 2012 | $10.37M | -11.7% |
| FY2011 | Sep 30, 2011 | $11.75M | -1.4% |
| FY2010 | Sep 30, 2010 | $11.91M | +98.1% |
| FY2009 | Sep 30, 2009 | $6.01M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $3.65M | -2.4% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $3.77M | -6.2% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $3.68M | -17.0% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $3.70M | -17.3% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $3.74M | -20.5% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $4.01M | -13.3% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $4.43M | +1.8% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $4.48M | -15.0% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $4.70M | -17.9% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $4.63M | -23.9% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $4.35M | -19.3% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $5.27M | -18.5% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $5.73M | -8.9% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $6.08M | -6.7% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $5.39M | -11.4% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $6.46M | +22.1% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $6.29M | -12.5% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $6.52M | +24.9% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $6.08M | +12.3% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $5.29M | +2.5% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $7.18M | +81.0% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $5.22M | +17.1% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $5.41M | +27.3% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $5.16M | +52.2% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $3.97M | +33.8% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $4.46M | +57.4% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $4.25M | +22.5% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $3.39M | +5.9% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $2.97M | +22.3% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $2.83M | -4.4% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $3.47M | +49.3% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $3.20M | +39.2% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $2.43M | -23.7% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $2.96M | -55.0% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $2.33M | -34.4% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $2.30M | -45.7% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $3.18M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $6.58M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $3.55M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $4.24M | – |
See a number that looks wrong?